AG Magazine • Health & Nutrition
Off-label testosterone for menopause is rising fast — and a new heart-risk signal just landed. According to a 2026 JAMA Medical News report, testosterone prescribing in the U.S. has risen 2.6-fold over the past decade, driven mostly by midlife women. Social feeds sell it as the missing piece of the menopause puzzle: more energy, sharper focus, a stronger body.
Then the data pushed back. Researchers at The Menopause Society’s annual meeting reported that postmenopausal women on testosterone had sharply higher rates of first-time cardiovascular events than matched women who weren’t taking it. Suddenly, the miracle hormone looks like a risk.
Get more like this — weekly.
One email a week. Research-backed wellness, translated into things you can actually do. No spam.
Here’s the contrarian truth: both camps are overselling. The hype ignores what the evidence actually supports, and the alarm ignores what an observational study can and can’t prove. This guide breaks down what the new signal shows, where testosterone therapy for women has real evidence, and the training moves that protect your heart no matter which side of the debate wins.
What Did the New Testosterone Heart-Risk Study Find?
A retrospective cohort study presented at The Menopause Society’s annual meeting found that postmenopausal women using testosterone had a 3.8% rate of new cardiovascular disease — events like heart attack, stroke, and heart failure — versus 0.5% in matched non-users. That is a hazard ratio of about 8. The study is observational and has not yet been peer-reviewed.
The researchers drew on a large U.S. health-records network, matching 3,164 women in each group. The gap persisted when they compared women on testosterone plus menopause hormone therapy against women on hormone therapy alone (3.2% vs. 0.5%). Still, the authors themselves described the results as hypothesis-generating and called for prospective validation.
Why does this matter right now? Because demand for testosterone for menopause is outrunning the evidence. Many women using it rely on products approved for men or compounded formulations, and this testosterone heart risk signal is one of the first large-scale looks at cardiovascular disease in women who actually use it.
Does testosterone increase heart attack risk in women?
The honest answer: we don’t know yet. An observational study shows association, not causation. Women prescribed testosterone may differ from non-users in ways matching can’t fully capture — how they got the prescription, what dose and formulation they used, how closely they were monitored.
Context matters, too. In absolute terms, the gap works out to roughly 38 events per 1,000 women versus 5 per 1,000. That’s a real difference worth taking seriously — but it’s a signal, not a verdict. And it lands in a thin evidence base: the Global Consensus Position Statement on testosterone for women notes that women at high cardiometabolic risk were excluded from the trials, and that long-term safety has not been established.
Testosterone for Menopause: Why Both Sides Are Overselling
If you’re hoping the men’s research settles the question, it doesn’t. And if you’ve been told testosterone fixes everything, the women’s research doesn’t back that up either.
Why the men’s heart data doesn’t transfer
The landmark TRAVERSE trial found testosterone was noninferior to placebo for major cardiac events in men — but Cleveland Clinic investigators stress the 2023 findings apply only to men aged 45 to 80 with confirmed hypogonadism. Even there, the testosterone group saw more atrial fibrillation, acute kidney injury, and pulmonary embolism. Female physiology, doses, and baseline risk are different. Borrowed reassurance is not evidence.
What is testosterone for menopause actually proven to do?
Far less than the hype implies. The 2019 consensus statement — foundational guidance endorsed by major menopause and endocrine societies — concludes the only evidence-based indication is hypoactive sexual desire disorder (HSDD) in postmenopausal women. It found insufficient evidence for cognition and no effect on general wellbeing.
A 2019 meta-analysis in The Lancet Diabetes & Endocrinology pooled 36 randomized trials with 8,480 participants. Testosterone improved sexual desire, arousal, and satisfaction, and no serious adverse events were recorded — but oral testosterone raised LDL cholesterol, while non-oral routes did not. Modest, specific benefits. Short trials. That’s the real picture of testosterone for menopause.
Why Postmenopausal Heart Risk Was Already Climbing
Here’s the part the headlines skip. Your heart risk was rising before anyone wrote a prescription for testosterone for menopause. A foundational 2020 American Heart Association scientific statement confirms cardiovascular disease is the leading cause of death in women, with a notable rise in risk after menopause — and lean muscle mass declines faster during the menopause transition.
The same AHA statement reports that only about 7% of midlife women meet physical activity recommendations. So ask yourself: are you debating a hormone while skipping the most proven lever you own? The testosterone question is real. It’s just not the biggest lever for postmenopausal heart health.
Is testosterone safe for women after menopause?
For a narrow group, short-term use looks reasonable. The consensus guidance considers off-label use of an approved male formulation reasonable for testosterone therapy for women when blood levels stay within the normal female range — under clinical supervision.
What “safe” has never meant is safe for decades, safe at high doses, or safe for women with existing heart risk. That gap is exactly where the new testosterone heart risk signal lands. If you already use menopause hormone therapy or testosterone, don’t stop on your own — bring this research to your clinician and decide together.
How to Protect Your Heart Before Considering Testosterone
Whether or not testosterone for menopause ends up in your plan, these moves build postmenopausal heart health on evidence, not hype — and they lower the baseline risk of cardiovascular disease in women regardless of hormones:
- Lift with intent. A 2024 meta-analysis of randomized trials found resistance training significantly improved upper- and lower-body strength and aerobic capacity in postmenopausal women.
- Train three days a week, progressively. A 2025 meta-analysis on bone density suggests high-intensity work (at least 70% of your one-rep max) three times weekly may be optimal for bone health.
- Know your numbers first. Blood pressure, lipid panel, fasting glucose, and family history should be on the table before any hormone conversation.
- If testosterone is offered, ask why. Is it for diagnosed HSDD? Is the dose physiologic for women? Is it non-oral? How will your levels be monitored?
- Wait for the paper. Conference findings change. Watch for peer-reviewed publication before treating this testosterone for menopause signal as settled — in either direction.
Competitive athletes have one more step: check your sport’s anti-doping rules before discussing any testosterone prescription.
⚡ PRO TIP
Bring a one-page “heart file” to your next appointment: recent blood pressure readings, your latest lipid panel and fasting glucose, family heart history, and every medication and supplement you take. Then ask one question: “What is my 10-year cardiovascular risk, and how would testosterone change it?” If no one can answer that clearly, you’re not ready to start — and that’s useful information, not a setback.
Train the Heart First. Treat the Hormone Second.
The debate over testosterone for menopause won’t be settled by a single conference abstract — or by a viral testimonial. What you can settle today is the foundation: a stronger body, a known risk profile, and a clinician who answers your questions with data.
You don’t need to pick a side to make a smart move. Hormones may have a role for some women, and only you and your clinician can weigh that tradeoff. But strength training, cardiovascular screening, and informed questions work for every woman, at every stage.
Your next step: this week, book a cardiovascular risk check with your clinician and schedule three strength sessions on your calendar. Build the base. Then make the hormone decision from strength, not from a headline.




No one seems to have shared their thoughts on this topic yet
Leave a comment so your voice will be heard first.